A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Plain-language summary

This study evaluates the real-world use of targeted therapies selected according to the tumor's molecular type in patients with advanced thyroid cancer. Patients with locally advanced or metastatic thyroid cancer not amenable to radical surgery, who have undergone target gene testing, may take part. The study is being conducted in Phase 4 and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 4

Status

Recruiting

Sponsor

Fudan University

Intervention

dabrafenib plus trametinib with or without PD-1 antibody, entrectinib or larotrectinib with or without anti-PD-1 antibdoy, pralsetinib or selpercatinib with or without anti-PD-1 antibdoy, anlotinib or anlotinib plus anti-PD-1 antibody, lenvatinib plus anti-PD-1 antibody, Other Targets: precise treatment based on the target

Start date

1/1/2020

Estimated completion

12/31/2028

Countries

China

Related genes

Locations

• Fuzhou, China
• Zhengzhou, China
• Wuhan, China
• Hohhot, China
• Shanghai, China
• Shanxi, China
• Hangzhou, China
• Beijing, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Patients volunteered to participate in this study and signed informed consent;
2. Each center can be enrolled in patients who meet the age of their own practice range, regardless of gender ;
3. Histologically diagnosed locally advanced or recurrent / metastatic thyroid cancer that cannot undergo radical surgery meets one of the following requirements:

   1. Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC);
   2. Differentiated thyroid carcinoma not suitable for iodine therapy;
   3. Medullary thyroid carcinoma (MTC);
   4. poorly differentiated thyroid cancer (PDTC) or anaplastic thyroid cancer (ATC);
4. Thyroid-related pathogenic or therapeutic target gene detection was performed before enrollment.

Exclusion Criteria:

1. Patients who are participating in clinical trials of other drugs;
2. There is evidence that the patients are pregnant or lactating;
3. Other situations that are not suitable for inclusion in this study.